Triple negative breast cancer: New therapeutic approaches and BRCA status
dc.contributor.author | Güney Eskiler, Gamze | |
dc.contributor.buuauthor | Çeçener, Gülşah | |
dc.contributor.buuauthor | Egeli, Ünal | |
dc.contributor.buuauthor | Tunca, Berrin Türkei | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | tr_TR |
dc.contributor.orcid | 0000-0001-7904-883X | tr_TR |
dc.contributor.orcid | 0000-0002-1619-6680 | tr_TR |
dc.contributor.researcherid | AAP-9988-2020 | tr_TR |
dc.contributor.researcherid | AAH-1420-2021 | tr_TR |
dc.contributor.researcherid | ABI-6078-2020 | tr_TR |
dc.contributor.scopusid | 6508156530 | tr_TR |
dc.contributor.scopusid | 55665145000 | tr_TR |
dc.contributor.scopusid | 6602965754 | tr_TR |
dc.date.accessioned | 2022-12-21T13:49:26Z | |
dc.date.available | 2022-12-21T13:49:26Z | |
dc.date.issued | 2018-04-25 | |
dc.description.abstract | Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led to the development of different therapeutic approaches. Besides, identification of TNBC subtypes contribute to investigation of the underlying molecular differences and development of new strategies for the treatment of TNBC patients. In this review, we discussed the definition and characteristic properties of TNBC. We summarized an up-to-date description of the reported clinical trials of novel targeted strategies especially PARP inhibitors (PARPi) due to novel and highly potent for the treatment of TNBC. Additionally, we reviewed published studies which investigated the prevalence and types of BRCA1/2 mutation in breast cancer patients to assess and draw attention of association of BRCA status with TNBC. Consequently, the definition subtype of TNBC has important predictive value for the development of new therapeutic agents in the treatment of TNBC. Additionally, the incidence and types of mutations in BRCA-related pathways may be affected by ethnic origin and contribute to the risk of developing TNBC. | en_US |
dc.identifier.citation | Eskiler, G. G. vd. (2018). ''Triple negative breast cancer: new therapeutic approaches and BRCA status''. APMIS, 126(5), 371-379. | en_US |
dc.identifier.endpage | 379 | tr_TR |
dc.identifier.issn | 0903-4641 | |
dc.identifier.issn | 1600-0463 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 29696717 | tr_TR |
dc.identifier.scopus | 2-s2.0-85045939792 | tr_TR |
dc.identifier.startpage | 371 | tr_TR |
dc.identifier.uri | https://doi.org/10.1111/apm.12836 | |
dc.identifier.uri | onlinelibrary.wiley.com/doi/10.1111/apm.12836 | |
dc.identifier.uri | http://hdl.handle.net/11452/30022 | |
dc.identifier.volume | 126 | tr_TR |
dc.identifier.wos | 000430912200002 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | APMIS | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Triple negative breast cancer | en_US |
dc.subject | BRCA1/2 | en_US |
dc.subject | Synthetic lethality | en_US |
dc.subject | Therapeutic agents | en_US |
dc.subject | PARP inhibitors | en_US |
dc.subject | Mutation carriers | en_US |
dc.subject | Targeted therapy | en_US |
dc.subject | Parp inhibitors | en_US |
dc.subject | Turkish breast | en_US |
dc.subject | Germline brca1 | en_US |
dc.subject | Ovarian | en_US |
dc.subject | Genes | en_US |
dc.subject | Susceptibility | en_US |
dc.subject | Management | en_US |
dc.subject | Families | en_US |
dc.subject | Immunology | en_US |
dc.subject | Microbiology | en_US |
dc.subject | Pathology | en_US |
dc.subject.emtree | BRCA1 protein | en_US |
dc.subject.emtree | BRCA2 protein | en_US |
dc.subject.emtree | Cytokeratin 17 | en_US |
dc.subject.emtree | Cytokeratin 5 | en_US |
dc.subject.emtree | Cytokeratin 6 | en_US |
dc.subject.emtree | Epidermal growth factor receptor | en_US |
dc.subject.emtree | Niraparib | en_US |
dc.subject.emtree | Olaparib | en_US |
dc.subject.emtree | Rucaparib | en_US |
dc.subject.emtree | Talazoparib | en_US |
dc.subject.emtree | Veliparib | en_US |
dc.subject.emtree | Nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor | en_US |
dc.subject.emtree | Cancer growth | en_US |
dc.subject.emtree | Cancer incidence | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Cancer staging | en_US |
dc.subject.emtree | Cancer surgery | en_US |
dc.subject.emtree | Cancer survival | en_US |
dc.subject.emtree | Disease free survival | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gene mutation | en_US |
dc.subject.emtree | Genetic risk | en_US |
dc.subject.emtree | Genomic instability | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Induced resistance | en_US |
dc.subject.emtree | Medical history | en_US |
dc.subject.emtree | Prediction | en_US |
dc.subject.emtree | Prevalence | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Triple negative breast cancer | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Triple negative breast cancer | en_US |
dc.subject.emtree | Tumor suppressor gene | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Genes, BRCA1 | en_US |
dc.subject.mesh | Genes, BRCA2 | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Poly(ADP-ribose) polymerase inhibitors | en_US |
dc.subject.mesh | Triple negative breast neoplasms | en_US |
dc.subject.scopus | Triple Negative Breast Neoplasms; Negative; Hormone Receptors | en_US |
dc.subject.wos | Immunology | en_US |
dc.subject.wos | Microbiology | en_US |
dc.subject.wos | Pathology | en_US |
dc.title | Triple negative breast cancer: New therapeutic approaches and BRCA status | en_US |
dc.type | Review | |
dc.wos.quartile | Q2 (Pathology) | en_US |
dc.wos.quartile | Q3 (Microbiology) | en_US |
dc.wos.quartile | Q4 (Immunology) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: